GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Haw Par Corp Ltd (SGX:H02) » Definitions » EV-to-EBITDA

Haw Par (SGX:H02) EV-to-EBITDA : -4.30 (As of Jun. 01, 2024)


View and export this data going back to 1969. Start your Free Trial

What is Haw Par EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Haw Par's enterprise value is S$-1,018.8 Mil. Haw Par's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was S$237.0 Mil. Therefore, Haw Par's EV-to-EBITDA for today is -4.30.

The historical rank and industry rank for Haw Par's EV-to-EBITDA or its related term are showing as below:

SGX:H02' s EV-to-EBITDA Range Over the Past 10 Years
Min: -9.19   Med: -0.07   Max: 11.12
Current: -4.31

During the past 13 years, the highest EV-to-EBITDA of Haw Par was 11.12. The lowest was -9.19. And the median was -0.07.

SGX:H02's EV-to-EBITDA is ranked better than
99.44% of 714 companies
in the Drug Manufacturers industry
Industry Median: 14.4 vs SGX:H02: -4.31

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-01), Haw Par's stock price is S$9.77. Haw Par's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was S$0.978. Therefore, Haw Par's PE Ratio for today is 9.99.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Haw Par EV-to-EBITDA Historical Data

The historical data trend for Haw Par's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Haw Par EV-to-EBITDA Chart

Haw Par Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.23 -3.17 -4.98 -6.23 -4.32

Haw Par Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.98 - -6.23 - -4.32

Competitive Comparison of Haw Par's EV-to-EBITDA

For the Drug Manufacturers - General subindustry, Haw Par's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Haw Par's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Haw Par's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Haw Par's EV-to-EBITDA falls into.



Haw Par EV-to-EBITDA Calculation

Haw Par's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=-1018.770/236.997
=-4.30

Haw Par's current Enterprise Value is S$-1,018.8 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Haw Par's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was S$237.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Haw Par  (SGX:H02) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Haw Par's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=9.77/0.978
=9.99

Haw Par's share price for today is S$9.77.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Haw Par's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was S$0.978.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Haw Par EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Haw Par's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Haw Par (SGX:H02) Business Description

Traded in Other Exchanges
Address
401 Commonwealth Drive, No. 03-03 Haw Par Technocentre, Singapore, SGP, 149598
Haw Par Corp Ltd is a drug manufacturing company that operates multiple brands. The company is to expand its core businesses through product brand extension, strategic alliances, and exploring potential acquisitions. Its operating segments include the Healthcare segment, Investments segment, and Others segment. The company generates maximum revenue from the Healthcare segment. Its Healthcare segment manufactures and distributes topical analgesic products under the Tiger Balm and Kwan Loong brands. Geographically, it generates a majority of its revenue from the ASEAN countries.

Haw Par (SGX:H02) Headlines

No Headlines